MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Avenue Therapeutics Cash and Cash Equivalents 2011-2026 | ATXI
Annual Cash and Cash Equivalents Avenue Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.59 M | 1.78 M | 6.71 M | 3.76 M | 3.13 M | 8.74 M | 2.67 M | 11.8 M | 197 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.8 M | 197 K | 4.6 M |
Quarterly Cash and Cash Equivalents Avenue Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.71 M | 3.33 M | 3.5 M | 2.59 M | 2.6 M | 4.92 M | 3.19 M | 1.78 M | 161 K | 1.57 M | 8.24 M | 6.71 M | 217 K | 890 K | 1.83 M | 3.76 M | 585 K | 1.12 M | 1.82 M | 3.13 M | 3.13 M | 3.13 M | 3.13 M | 8.74 M | 8.74 M | 8.74 M | 8.74 M | 2.67 M | 2.67 M | 2.67 M | 2.67 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 197 K | 197 K | 32 K | 197 K | 14 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.8 M | 14 K | 3.96 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
24.6 M | $ 3.01 | 3.79 % | $ 233 M |  USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.08 | 0.65 % | $ 7.41 B |  Australia |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.99 | 1.02 % | $ 508 M |  Britain |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
89.4 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
560 M | $ 213.24 | 1.87 % | $ 5 B |  Danmark |
 |
BioVie
BIVI
|
17.5 M | $ 1.16 | 2.65 % | $ 1.71 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
37.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M |  Canada |
 |
Bellicum Pharmaceuticals
BLCM
|
21.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
144 M | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
222 M | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
9.76 B | $ 95.2 | -0.08 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 0.2 | 8.46 % | $ 435 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
152 M | $ 26.78 | -0.81 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
2.63 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
72.9 M | $ 9.61 | 0.63 % | $ 141 M | USA |
 |
Catalyst Biosciences
CBIO
|
33.5 M | $ 11.86 | 2.24 % | $ 781 M | USA |
 |
Calithera Biosciences
CALA
|
59.5 M | - | -10.95 % | $ 876 K | USA |
 |
Certara
CERT
|
179 M | $ 8.81 | -0.56 % | $ 1.41 B | USA |
 |
Celldex Therapeutics
CLDX
|
28.4 M | $ 27.16 | 2.76 % | $ 1.75 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
220 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Cellectis S.A.
CLLS
|
143 M | $ 4.84 | 1.26 % | $ 116 M | France |
 |
Cellectar Biosciences
CLRB
|
9.56 M | $ 2.95 | 7.66 % | $ 36.1 M | USA |
 |
Axon Enterprise
AXON
|
455 M | $ 567.93 | -0.73 % | $ 43 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.6 | 1.96 % | $ 16.3 M | USA |
 |
AstraZeneca PLC
AZN
|
5.49 B | $ 91.93 | -0.63 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 8.92 | -1.0 % | $ 1.46 B | Britain |
 |
ChromaDex Corporation
CDXC
|
44.5 M | - | -0.88 % | $ 598 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
172 M | $ 11.29 | -3.01 % | $ 730 M | USA |